A previous study of cancer cells not specific to melanoma reported paradoxical activation of MEK1/2 upon MEK1/2 inhibition in a BRAF-/NRAS-wild-type setting, citing that signaling in these cells is regulated by receptor tyrosine kinases (RTKs) [35] (Supplementary Table S4). This evidence concerns the gene BRAF and cancer.